Fusion Pharmaceuticals
FUSN
FUSN was delisted on the 3rd of June, 2024.
31 hedge funds and large institutions have $89.5M invested in Fusion Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 5 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
2.24% more ownership
Funds ownership: 61.26% → 63.51% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 34 → 31 (-3)
40% less capital inflows, than outflows
Capital inflows: $770K | Capital outflows: $1.27M
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS O'Connor
Chicago,
Illinois
|
+$431K |
| 2 |
Leonteq Securities
Zurich,
Switzerland
|
+$132K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$124K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$46.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$883K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$152K |
| 3 |
Tekla Capital Management
Boston,
Massachusetts
|
-$146K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$44K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$39.8K |
FUSN Hedge Fund Activity: Q4 2022 in Review
31 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals (FUSN) for Q4 2022, worth a combined $89.5M — up 11% from $80.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FUSN and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was UBS O'Connor, adding an estimated $431K. The largest seller was Fidelity Investments, cutting an estimated $883K.
- 31 institutional investors held Fusion Pharmaceuticals (FUSN) as of Q4 2022, down from 34 in Q3 2022.
- Funds reported $89.5M of Fusion Pharmaceuticals stock for Q4 2022, up 11% quarter-over-quarter.
- 2 funds opened new Fusion Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest Fusion Pharmaceuticals buyer in Q4 2022 was UBS O'Connor, an estimated $431K added.
- The largest Fusion Pharmaceuticals seller in Q4 2022 was Fidelity Investments, an estimated $883K sold.
Based on aggregated 13F filings for Q4 2022.